Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT in Oligometastatic Hormone-Sensitive Prostate Cancer
NCT04115007Phase 3Active, not recruiting
- Sponsor
- Unicancer
- Start
- Jun 2020
- Primary completion
- Jun 2026
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Unicancer. Primary endpoint: Castration-resistant prostate cancer free survival at 1 year. Started Jun 2020; status: active, not recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04115007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115007.